Pharmexa's share capital and number of voting rights as of May 31, 2007


In accordance with section 17 of the Danish executive order No. 226 of March
15, 2007, on disclosure requirements for issuers of shares, Pharmexa provides
the following information: 

•	The share capital of Pharmexa amounts to DKK 414,543,950
•	Each share of DKK 10 carries one voting right
•	The total number of voting rights is 41,454,395





Hørsholm, June 1, 2007


Jakob Schmidt
Chief Executive Officer


Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45
4516 2525 
Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45
4060 2558 


Note to editors: Pharmexa A/S is a leading company in the field of active
immunotherapy and vaccines for the treatment of cancer, serious chronic and
infectious diseases. Pharmexa's proprietary technology platforms are broadly
applicable, allowing the company to address critical targets in cancer, bone
degeneration and Alzheimer's disease, as well as serious infectious diseases
such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001,
a peptide vaccine that has entered phase III trials in pancreatic cancer and
phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II.
Collaborative agreements include H. Lundbeck, Innogenetics, IDM Pharma,
ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark,
Norway and USA, Pharmexa employs approximately 105 people and is listed on the
Copenhagen Stock Exchange under the trading symbol PHARMX.

Pièces jointes

pharmexa press release 2007-20-uk.pdf
GlobeNewswire